Description
Icosavax Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens.
The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The Company is also developing two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, IVX-411 and IVX-421, with a Phase I/II clinical trial of IVX-411.